Indaptus Therapeutics Inc Cash Flow Conversion Efficiency
Indaptus Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has a cash flow conversion efficiency ratio of -0.169x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.93 Million) by net assets ($11.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Indaptus Therapeutics Inc (2008–2025)
Cash flow conversion efficiency of Indaptus Therapeutics Inc from 2008 to 2025. This chart illustrates how Indaptus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INDP live share price for real-time trading data and today's change.
Indaptus Therapeutics Inc Cash Flow Conversion Ratio Explained
Indaptus Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Indaptus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indaptus Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Indaptus Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Standard Chemical & Pharmaceutical Co Ltd
TW:1720
|
0.057x |
|
Beijing Integrity Technology Co. Ltd. A
SHG:688244
|
N/A |
|
StealthGas Inc
F:S6W
|
0.024x |
|
Gladstone Land Corporation
NASDAQ:LAND
|
0.030x |
|
DITTO (THAILAND)
BK:DITTO-R
|
-0.028x |
|
Yuen Foong Yu Consumer Prod
TW:6790
|
0.071x |
|
Apollo Commercial Real Estate Finance Inc
NYSE:ARI
|
0.007x |
|
FTAI Infrastructure Inc.
NASDAQ:FIP
|
0.061x |
Annual Cash Flow Conversion Efficiency for Indaptus Therapeutics Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Indaptus Therapeutics Inc from 2008 to 2025. Review INDP free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.15 Million | $-14.82 Million | -4.703x | -50.56% |
| 2024-12-31 | $3.94 Million | $-12.32 Million | -3.124x | -181.42% |
| 2023-12-31 | $12.08 Million | $-13.41 Million | -1.110x | -109.05% |
| 2022-12-31 | $24.63 Million | $-13.08 Million | -0.531x | -68.83% |
| 2021-12-31 | $35.90 Million | $-11.29 Million | -0.315x | -102.25% |
| 2020-12-31 | $-237.70K | $-3.32 Million | 13.987x | +655.47% |
| 2019-12-31 | $11.54 Million | $-29.05 Million | -2.518x | -245.03% |
| 2018-12-31 | $53.55 Million | $-39.08 Million | -0.730x | -93.89% |
| 2017-12-31 | $58.80 Million | $-22.13 Million | -0.376x | +28.82% |
| 2016-12-31 | $22.70 Million | $-12.01 Million | -0.529x | -137.68% |
| 2015-12-31 | $35.63 Million | $-7.93 Million | -0.222x | +55.64% |
| 2014-12-31 | $9.48 Million | $-4.75 Million | -0.501x | -37.70% |
| 2013-12-31 | $9.30 Million | $-3.38 Million | -0.364x | +44.59% |
| 2012-12-31 | $6.85 Million | $-4.50 Million | -0.657x | +5.12% |
| 2011-12-31 | $7.77 Million | $-5.38 Million | -0.693x | -84.96% |
| 2010-12-31 | $11.51 Million | $-4.31 Million | -0.375x | +80.86% |
| 2009-12-31 | $1.57 Million | $-3.08 Million | -1.957x | -208.82% |
| 2008-12-31 | $-2.10 Million | $-3.78 Million | 1.798x | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more